These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 22422300

  • 1. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A, Rosso R, Loregian A, Pagni S, Sormani MP, Cenderello G, Palù G, Viscoli C.
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [Abstract] [Full Text] [Related]

  • 2. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C, Barrail A, Goujard C, Taburet AM.
    Clin Pharmacokinet; 2005 Oct; 44(10):1035-50. PubMed ID: 16176117
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, Barassi A, Maserati R, Sighinolfi L, D'Arminio Monforte A, Melzi D'Eril GV.
    Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015
    [Abstract] [Full Text] [Related]

  • 5. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.
    Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
    [Abstract] [Full Text] [Related]

  • 6. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [Abstract] [Full Text] [Related]

  • 7. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E, Tribut O, Tattevin P, Arvieux C, Perré P, Raffi F, Jolliet P.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [Abstract] [Full Text] [Related]

  • 8. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ, Gatell JM, Flores J, Santos J, Vera-Médez F, Clotet B, Moreno A, Pérez-Molina JA, Vendrell B, Serrano O.
    HIV Clin Trials; 2009 Jul; 10(4):269-75. PubMed ID: 19723614
    [Abstract] [Full Text] [Related]

  • 9. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.
    HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
    [Abstract] [Full Text] [Related]

  • 10. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N.
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [Abstract] [Full Text] [Related]

  • 11. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [Abstract] [Full Text] [Related]

  • 12. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [Abstract] [Full Text] [Related]

  • 13. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW, AIDS Clinical Trials Group 5201 Study Team.
    JAMA; 2006 Aug 16; 296(7):806-14. PubMed ID: 16905786
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D.
    Pharmacotherapy; 2013 Mar 16; 33(3):284-94. PubMed ID: 23456732
    [Abstract] [Full Text] [Related]

  • 15. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Karlström O, Josephson F, Sönnerborg A.
    J Acquir Immune Defic Syndr; 2007 Apr 01; 44(4):417-22. PubMed ID: 17159658
    [Abstract] [Full Text] [Related]

  • 16. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.
    HIV Med; 2010 May 01; 11(5):326-33. PubMed ID: 20070407
    [Abstract] [Full Text] [Related]

  • 17. Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients.
    Avihingsanon A, Kerr SJ, Punyawudho B, van der Lugt J, Gorowara M, Ananworanich J, Lange JM, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K.
    AIDS Res Hum Retroviruses; 2013 Dec 01; 29(12):1541-6. PubMed ID: 24088045
    [Abstract] [Full Text] [Related]

  • 18. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.
    Antivir Ther; 2007 Dec 01; 12(5):825-30. PubMed ID: 17713166
    [Abstract] [Full Text] [Related]

  • 19. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
    von Hentig N, Kaykhin P, Stephan C, Babacan E, Stürmer M, Staszewski S, Lötsch J.
    Antimicrob Agents Chemother; 2008 Jun 01; 52(6):2273-5. PubMed ID: 18411323
    [Abstract] [Full Text] [Related]

  • 20. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Gervasoni C, Riva A, Rizzardini G, Clementi E, Galli M, Cattaneo D.
    Antivir Ther; 2015 Jun 01; 20(4):449-51. PubMed ID: 25279606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.